These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28408175)

  • 1. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.
    Clausen TM; Pereira MA; Al Nakouzi N; Oo HZ; Agerbæk MØ; Lee S; Ørum-Madsen MS; Kristensen AR; El-Naggar A; Grandgenett PM; Grem JL; Hollingsworth MA; Holst PJ; Theander T; Sorensen PH; Daugaard M; Salanti A
    Mol Cancer Res; 2016 Dec; 14(12):1288-1299. PubMed ID: 27655130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility.
    Spliid CB; Toledo AG; Sanderson P; Mao Y; Gatto F; Gustavsson T; Choudhary S; Saldanha AL; Vogelsang RP; Gögenur I; Theander TG; Leach FE; Amster IJ; Esko JD; Salanti A; Clausen TM
    J Biol Chem; 2021 Dec; 297(6):101391. PubMed ID: 34762909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.
    Agerbaek MØ; Pereira MA; Clausen TM; Pehrson C; Oo HZ; Spliid C; Rich JR; Fung V; Nkrumah F; Neequaye J; Biggar RJ; Reynolds SJ; Tosato G; Pullarkat ST; Ayers LW; Theander TG; Daugaard M; Bhatia K; Nielsen MA; Mbulaiteye SM; Salanti A
    Int J Cancer; 2017 Apr; 140(7):1597-1608. PubMed ID: 27997697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
    Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
    Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
    BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
    Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
    PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
    Salanti A; Clausen TM; Agerbæk MØ; Al Nakouzi N; Dahlbäck M; Oo HZ; Lee S; Gustavsson T; Rich JR; Hedberg BJ; Mao Y; Barington L; Pereira MA; LoBello J; Endo M; Fazli L; Soden J; Wang CK; Sander AF; Dagil R; Thrane S; Holst PJ; Meng L; Favero F; Weiss GJ; Nielsen MA; Freeth J; Nielsen TO; Zaia J; Tran NL; Trent J; Babcook JS; Theander TG; Sorensen PH; Daugaard M
    Cancer Cell; 2015 Oct; 28(4):500-514. PubMed ID: 26461094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
    Schardt J; Roth B; Seiler R
    World J Urol; 2019 Sep; 37(9):1759-1765. PubMed ID: 30392011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malaria Biomimetic for Tumor Targeted Drug Delivery.
    Pihl J; Clausen TM; Zhou J; Krishnan N; Ørum-Madsen MS; Gustavsson T; Dagil R; Daugaard M; Choudhary S; Foged C; Esko JD; Zhang L; Fang RH; Salanti A
    ACS Nano; 2023 Jul; 17(14):13500-13509. PubMed ID: 37435892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
    Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
    J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection.
    Zhang PF; Wu ZY; Zhang WB; He YQ; Chen K; Wang TM; Li H; Zheng H; Li DH; Yang DW; Zhou T; Deng CM; Liao Y; Xue WQ; Cao LJ; Li XZ; Zhang JB; Dong SQ; Wang F; Zheng MQ; Zhang WL; Mu J; Jia WH
    Nat Commun; 2023 Feb; 14(1):645. PubMed ID: 36746966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
    Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
    Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.
    Clausen TM; Kumar G; Ibsen EK; Ørum-Madsen MS; Hurtado-Coll A; Gustavsson T; Agerbæk MØ; Gatto F; Todenhöfer T; Basso U; Knowles MA; Sanchez-Carbayo M; Salanti A; Black PC; Daugaard M
    Cell Death Discov; 2020; 6():65. PubMed ID: 32793395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
    Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.